Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

09/10/2015 - 3 minutes

As we reported last Monday, the AbbVieGalapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for CF types II & III has gotten through phase I with promising results.

Abbvie galapgosGalapagos, from Belgium, has several key therapeutic areas in its clinical pipeline including rheumatoid arthritis, inflammatory diseases and Cystic Fibrosis (CF). Since their rheumatoid partnership with AbbVie recently (and infamously) fell through, it is encouraging to see their other AbbVie collaboration on Cystic Fibrosis research hasn’t also turned sour.

Cystic Fibrosis is a chronic heritable disease arising from the mutation of the CFTR transmembrane protein, which tansports chloride ions across all mucous membranes. Since CF affects around 80,000 people across the world, the Galapagos candidate GLPG1837 looks to treat this awful disease at the CFTR-gene level.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member